Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. LeBeau on the Potential Utility of Shark VNAR Proteins in Prostate Cancer

January 21st 2022

Aaron LeBeau, PhD, discusses the potential of shark variable domain of new antigen receptor proteins in prostate cancer.

Dr. Chandra on Assessing Mitochondrial Function to Inform Outcomes in Prostate Cancer

January 19th 2022

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

Dr. Woloszynska on the Need to Assess Biological Factors of Racial Disparities in Prostate Cancer

January 19th 2022

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

January 18th 2022

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Dr. Gomella on the Challenges of Optimizing PSA as a Biomarker in Prostate Cancer

January 13th 2022

Leonard G. Gomella, MD, discusses the challenges of optimizing prostate-specific antigen as a biomarker in prostate cancer.

Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment Journey

January 11th 2022

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Dr. Morris on Logistical Challenges of Using 177Lu-PSMA-617 in Prostate Cancer

January 11th 2022

Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer.

Pembrolizumab Plus Enzalutamide Continues to Produce Antitumor Activity in Abiraterone Acetate-Pretreated mCRPC

January 11th 2022

The combination of pembrolizumab and enzalutamide continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who were previously treated with abiraterone acetate, according to data from cohort C of the phase 1b/2 KEYNOTE-365 trial.

Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

January 10th 2022

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Black Men Derive Improved Outcomes With Definitive Radiotherapy in Localized Prostate Cancer

January 10th 2022

Black men with localized prostate cancer who had been treated with definitive radiotherapy had a lower likelihood of experiencing biochemical recurrence, distant metastasis, and prostate cancer–specific mortality compared with White men despite having more aggressive disease.

Roswell Park Receives Nearly $1 Million to Address Race-Related Disparities in Prostate Cancer

January 6th 2022

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

Dr. Zurita-Saavedra on Emerging Frontline Therapies in Metastatic HSPC

December 22nd 2021

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

December 22nd 2021

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Dr. Dorff on the Clinical Implications of the ARAMIS Trial in Nonmetastatic CRPC

December 21st 2021

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

December 20th 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

FDA Approves TLX591-CDx for Prostate Cancer Imaging

December 20th 2021

The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.

Dr. Zurita-Saavedra on Leveraging Antiandrogen Agents in Metastatic HSPC

December 20th 2021

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

December 17th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Dr. Siddiqui on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

December 14th 2021

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Shore on the Rationale for the Phase 2 ENACT Trial in Prostate Cancer

December 8th 2021

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.